CN1579514A - 一种治疗慢性肾功能衰竭的药物及其制备方法和用途 - Google Patents
一种治疗慢性肾功能衰竭的药物及其制备方法和用途 Download PDFInfo
- Publication number
- CN1579514A CN1579514A CN 200410026488 CN200410026488A CN1579514A CN 1579514 A CN1579514 A CN 1579514A CN 200410026488 CN200410026488 CN 200410026488 CN 200410026488 A CN200410026488 A CN 200410026488A CN 1579514 A CN1579514 A CN 1579514A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- medicine
- kidney
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 109
- 229940079593 drug Drugs 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 10
- 230000001684 chronic effect Effects 0.000 title abstract description 16
- 230000007812 deficiency Effects 0.000 claims abstract description 27
- 208000020832 chronic kidney disease Diseases 0.000 claims description 42
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 40
- 210000004369 blood Anatomy 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 36
- 210000000952 spleen Anatomy 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000009636 Huang Qi Substances 0.000 claims description 25
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 18
- 241000756943 Codonopsis Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 14
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 230000003907 kidney function Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract description 2
- 241000219061 Rheum Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 58
- 239000000047 product Substances 0.000 description 50
- 241000700159 Rattus Species 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- 238000000465 moulding Methods 0.000 description 27
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 24
- 229930024421 Adenine Natural products 0.000 description 22
- 229960000643 adenine Drugs 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 18
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000005239 tubule Anatomy 0.000 description 13
- 208000004880 Polyuria Diseases 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 230000035619 diuresis Effects 0.000 description 11
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000001647 Renal Insufficiency Diseases 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 8
- 201000006370 kidney failure Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 238000000151 deposition Methods 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000004459 forage Substances 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000037157 Azotemia Diseases 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 206010013990 dysuria Diseases 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000005991 hyperphosphatemia Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- XFBOJHLYDJZYSP-UHFFFAOYSA-N 2,8-dioxoadenine Chemical compound N1C(=O)N=C2NC(=O)NC2=C1N XFBOJHLYDJZYSP-UHFFFAOYSA-N 0.000 description 2
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013647 Drowning Diseases 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 2
- 208000031816 Pathologic Dilatation Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010041956 Stasis syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000005634 blind loop syndrome Diseases 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000004939 coking Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000590988 Danainae Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000003899 Foreign-Body Granuloma Diseases 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000007546 Giant Cell Granuloma Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000002560 nonimmunologic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000009705 sanhuang Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000010243 sho-seiryu-to Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
正常对照组 | 造型对照组 | 造型+该产品0.15g/kg | 造型+该产品0.38g/kg | 造型+该产品0.94g/kg | ||
BUN(mmoL/L) | 2周 | 9.70±1.65(6) | 25.44±3.02##(4) | 21.60±4.80(4) | 15.80±5.23*(4) | 17.31±2.93**(4) |
4周 | 10.98±5.94(8) | 48.78±7.52##(8) | 44.90±13.57(8) | 44.58±14.17(8) | 35.47±8.28**(8) | |
7周 | 9.46±0.71(8) | 53.94±9.82##(8) | 32.63±6.10**(8) | 33.34±8.28**(8) | 35.25±6.43**(8) | |
Scr(μmoL/L) | 2周 | 119.3±36.2(6) | 223.7±36.2##(4) | 172.4±30.9(4) | 129.9±33.6**(4) | 137.0±18.6**(4) |
4周 | 190.1±87.5(8) | 473.8±282.9#(8) | 476.5±207.7(8) | 240.4±56.6*(8) | 236.0±48.6*(8) | |
7周 | 116.7±45.1(8) | 413.7±26.5##(8) | 255.5±38.0**(8) | 236.9±61.0**(8) | 256.4±65.4**(8) |
正常对照组 | 造型对照组 | 造型+该产品0.15g/kg | 造型+该产品0.38g/kg | 造型+该产品0.94g/kg | ||
红细胞计数RBC(1012/L) | 2周 | 7.58±0.30(6) | 6.85±0.50(4) | 7.46±0.82(4) | 6.94±0.40(4) | 6.97±0.26(4) |
4周 | 7.73±0.22(8) | 5.80±0.82##(8) | 6.10±0.78(8) | 6.66±0.76*(8) | 6.68±0.71*(8) | |
7周 | 6.51±0.27(8) | 4.94±0.68##(8) | 5.12±1.08(8) | 5.23±0.79(8) | 5.41±0.49(8) | |
血红蛋白HGB(g/L) | 2周 | 114±6(6) | 135±10(4) | 144±9(4) | 135±8(4) | 137±8(4) |
4周 | 167±31(8) | 138±10#(8) | 135±12(8) | 133±9(8) | 148±12*(8) | |
7周 | 139±3(8) | 98±13##(8) | 108±8(8) | 111±8*(8) | 109±5*(8) | |
红细胞比积HCT(%) | 2周 | 37.3±1.5(6) | 33.3±2.2##(4) | 36.8±1.3*(4) | 33.9±2.4(4) | 34.1±1.7(4) |
4周 | 41.3±1.15(8) | 28.8±3.9#(8) | 29.7±4.1(8) | 31.5±4.7(8) | 35.2±5.8*(8) | |
7周 | 29.6±2.8(8) | 19.3±3.7##(8) | 21.5±5.0(8) | 26.2±5.3**(8) | 23.3±3.1*(8) | |
红细胞平均体积MCV(μm2) | 2周 | 49.3±1.5(6) | 48.8±1.7(4) | 49.3±1.3(4) | 48.8±1.5(4) | 48.8±1.7(4) |
4周 | 53.4±1.4(8) | 49.3±2.3##(8) | 48.6±1.3(8) | 49.4±2.3(8) | 49.5±1.6(8) | |
7周 | 44.0±4.0(8) | 38.6±3.9#(8) | 43.4±5.2(8) | 46.0±4.5**(8) | 45.1±2.2**(8) |
K(mmoL/L) | Na(mmoL/L) | Ca(mmoL/L) | P(mmoL/L) | 尿酸μmoL/L | 胆固醇(mmoL/L) | 中分子物质(μ/dL) | |
正常组 | 6.3±1.0(11) | 140.9±0.9(11) | 2.07±0.15(11) | 3.06±0.87(11) | 285.5±130.8(11) | 1.58±0.18(11) | 125.9±15.3(11) |
模型组 | 6.6±0.94(9) | 144.2±3.6#(9) | 2.0±0.14(9) | 5.26±1.55##(9) | 237.9±160.6(9) | 2.18±0.51##(9) | 152.6±15.3##(9) |
肾重(g) | 肾/体重量比值(%) | |
正常对照组 | 1.72±0.28(11) | 0.72±0.09 |
模型对照组 | 5.01±0.62(9)# | 2.84±0.24# |
造型+该产品0.15g/kg | 3.49±0.71(7)* | 1.88±0.33* |
造型+屎毒清0.38g/kg | 3.26±0.28(11)* | 1.81±0.38* |
造型+该产品0.94g/kg | 3.36±0.27(10)* | 1.84±0.23* |
正常对照组 | 造型对照组 | 该产品0.45g/kg | 该产品1.35g/kg | ||
BUN(mmoL/L) | 4周 | 9.70±1.65(6) | 25.44±3.02##(4) | 21.60±4.80(4) | 15.80±5.23*(4) |
8周 | 10.98±5.94(8) | 48.78±7.52##(8) | 44.90±13.57(8) | 44.58±14.17(8) | |
Scr(μmoL/L) | 4周 | 119.3±36.2(6) | 223.7±36.2##(4) | 172.4±30.9(4) | 129.9±33.6**(4) |
8周 | 190.1±87.5(8) | 473.8±282.9#(8) | 476.5±207.7(8) | 240.4±56.6*(8) |
正常对照组 | 造型对照组 | 该产品0.45g/kg | 该产品1.35g/kg | ||
RBC(1012/L) | 4周 | 6.50±0.77(7) | 5.16±0.41##(7) | 5.78±0.89(5) | 5.82±0.43*(8) |
8周 | 6.44±0.58(7) | 3.35±0.83##(10) | 4.29±0.60*(9) | 4.29±0.55*(8) | |
HGB(g/L) | 4周 | 98.8±8.3(8) | 83.4±8.0##(7) | 88.8±7.1(5) | 84.7±5.3(7) |
8周 | 127.7±15.1(7) | 62.7±9.6##(10) | 79.6±12.1*(10) | 80.3±9.3**(9) | |
HCT(%) | 4周 | 32.5±3.0(8) | 26.5±3.8##(7) | 27.2±2.8(5) | 26.4±1.8(6) |
8周 | 31.4±2.6(7) | 16.5±3.5##(10) | 21.0±4.4*(9) | 20.3±2.8(9) | |
MCV(fL) | 4周 | 51.1±4.3(8) | 48.1±1.8(7) | 48.0±2.5(5) | 47.9±3.9(7) |
8周 | 48.7±1.8(7) | 49.0±6.9(10) | 48.7±4.7(9) | 47.7±4.4(9) | |
MCH(pg) | 4周 | 15.7±0.86(7) | 15.8±0.85(7) | 16.0±0.71(5) | 15.3±0.92(7) |
8周 | 19.8±1.2(7) | 21.3±4.5(10) | 19.1±0.7(9) | 18.7±1.0(9) | |
MCHC | 4周 | 31.3±1.2(7) | 32.8±1.4(7) | 33.4±0.7(5) | 32.1±1.3(7) |
8周 | 40.5±1.6(7) | 43.6±8.1(10) | 39.5±3.4(9) | 39.7±3.4(9) |
正常对照组 | 模型对照组 | 该产品0.45g/kg | 该产品1.35g/kg | |
肾重/体重比值(%) | 0.62±0.06(9) | 2.54±0.50##(10) | 1.63±0.24**(10) | 1.39±0.13**(9) |
N | 结晶沉积物 面积(μm2) | 灰度值 | N | 肾小管 面积(μm2) | |
正常组 | 1396 | 0.292±0.406** | |||
模型组(空白对照组) | 1169 | 42.601±212.043 | 14.316±39.149 | 657 | 0.757±0.706 |
该产品大剂量组(1.35g/kg) | 240 | 0.238±0.222** | 3.177±1.979** | 658 | 0.909±1.104** |
该产品小剂量组(0.45g/kg) | 146 | 0.488±0.545**## | 10.181±20.134*## | 601 | 0.783±1.115## |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410026488 CN1269508C (zh) | 2004-03-17 | 2004-03-17 | 一种治疗慢性肾功能衰竭药物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410026488 CN1269508C (zh) | 2004-03-17 | 2004-03-17 | 一种治疗慢性肾功能衰竭药物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1579514A true CN1579514A (zh) | 2005-02-16 |
CN1269508C CN1269508C (zh) | 2006-08-16 |
Family
ID=34582004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410026488 Expired - Lifetime CN1269508C (zh) | 2004-03-17 | 2004-03-17 | 一种治疗慢性肾功能衰竭药物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1269508C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101954052A (zh) * | 2010-10-25 | 2011-01-26 | 姜沛良 | 治疗癌症的中药及其制备方法 |
CN103446558A (zh) * | 2013-07-26 | 2013-12-18 | 杨德俊 | 一种治疗慢性肾炎的中药 |
CN104013875A (zh) * | 2014-05-16 | 2014-09-03 | 王康琪 | 一种降血压黑膏药及其制备方法 |
CN105998523A (zh) * | 2016-05-11 | 2016-10-12 | 张春花 | 降磷补骨药及其制备方法 |
CN106138607A (zh) * | 2016-07-26 | 2016-11-23 | 马玉珍 | 一种治疗肾病综合征的药物 |
-
2004
- 2004-03-17 CN CN 200410026488 patent/CN1269508C/zh not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101954052A (zh) * | 2010-10-25 | 2011-01-26 | 姜沛良 | 治疗癌症的中药及其制备方法 |
CN103446558A (zh) * | 2013-07-26 | 2013-12-18 | 杨德俊 | 一种治疗慢性肾炎的中药 |
CN103446558B (zh) * | 2013-07-26 | 2015-09-23 | 杨德俊 | 一种治疗慢性肾炎的中药 |
CN104013875A (zh) * | 2014-05-16 | 2014-09-03 | 王康琪 | 一种降血压黑膏药及其制备方法 |
CN104013875B (zh) * | 2014-05-16 | 2018-07-06 | 王康琪 | 一种降血压黑膏药及其制备方法 |
CN105998523A (zh) * | 2016-05-11 | 2016-10-12 | 张春花 | 降磷补骨药及其制备方法 |
CN106138607A (zh) * | 2016-07-26 | 2016-11-23 | 马玉珍 | 一种治疗肾病综合征的药物 |
Also Published As
Publication number | Publication date |
---|---|
CN1269508C (zh) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100342889C (zh) | 一种治疗痛风的中药制剂及其制备方法和应用 | |
CN1836720A (zh) | 一种治疗关节炎或痛风的中药组合物及其制备方法 | |
CN1833688A (zh) | 治疗胃及十二指肠溃疡、慢性胃炎的药物及其制备方法 | |
CN1228074C (zh) | 治疗免疫功能低下或紊乱的中药 | |
CN106362020B (zh) | 一种具有改善通便作用的松花粉组合物及其制备方法 | |
CN1127657A (zh) | 双补降糖胶囊及其制作方法 | |
CN1269508C (zh) | 一种治疗慢性肾功能衰竭药物的制备方法 | |
CN1628768A (zh) | 一种治疗痛风病及其症状的药物 | |
CN1634352A (zh) | 复方消渴清糖降脂制剂及其制备方法 | |
CN101053619A (zh) | 一种治疗肺纤维化的药物 | |
CN1927331A (zh) | 一种治疗慢性心力衰竭的中药制剂 | |
CN1785330A (zh) | 一种治疗高血压的药物及其制备方法 | |
CN1293899C (zh) | 一种用于治疗高血压的藤丹胶囊 | |
CN1712055A (zh) | 一种治疗泌尿系结石的中药制剂(溶石胶囊) | |
CN1772257A (zh) | 三七脂肝制剂及其制备方法 | |
CN101028488A (zh) | 治疗慢性咽炎、食道炎和食道癌的中成药 | |
CN100342888C (zh) | 一种治疗前列腺增生的中药制剂及其制备方法和应用 | |
CN1087627C (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN1063649C (zh) | 一种红参山楂保健酒 | |
CN1234390C (zh) | 一种治疗积水、水肿的药物及其制造方法 | |
CN1269501C (zh) | 一种治疗慢性结肠炎的药物及制备方法 | |
CN1301725C (zh) | 一种治疗糖尿病的根粉消渴胶囊 | |
CN1883641A (zh) | 一种治疗脾肾阳虚和抗衰健身的药物及其制备方法 | |
CN1899385A (zh) | 一种治疗慢性肾功能衰竭中药复方注射剂的制备工艺以及应用 | |
CN1840101A (zh) | 具有祛风除湿、通经络、散寒止痛功能的中药及制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CONSUN PHARMACEUTICAL(INNER MONGOLIA) CO., LTD Free format text: FORMER OWNER: GUANGZHOU CONSUN PHARMACEUTICAL CO., LTD. Effective date: 20100129 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100129 Address after: Inner Mongolia Tongliao city Kerqinzuoyihouqi Ganqika Industrial Park No. 2 North Road Patentee after: Kangchen Pharmaceutical (Inner Mongolia) Co.,Ltd. Address before: No. 71, Dongpeng Avenue, Guangzhou economic and Technological Development Zone, Guangzhou, Guangdong Patentee before: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Kangchen Pharmaceutical (Inner Mongolia) Co.,Ltd. Assignor: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. Contract fulfillment period: 2009.10.1 to 2016.9.30 Contract record no.: 2009150000031 Denomination of invention: Medicine for treating chronic renal faiture, its preparation method and use Granted publication date: 20060816 License type: Exclusive license Record date: 20091124 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.10.1 TO 2016.9.30; CHANGE OF CONTRACT Name of requester: CONSUN PHARMACEUTICAL(INNER MONGOLIA) CO., LTD Effective date: 20091124 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Kangchen Pharmaceutical (Inner Mongolia) Co.,Ltd. Assignor: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. Contract record no.: 2009150000031 Date of cancellation: 20210922 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050216 Assignee: Kangchen Pharmaceutical (Horgos) Co.,Ltd. Assignor: Kangchen Pharmaceutical (Inner Mongolia) Co.,Ltd. Contract record no.: X2021990000581 Denomination of invention: A preparation method of medicine for treating chronic renal failure Granted publication date: 20060816 License type: Common License Record date: 20210922 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221111 Address after: 835221 No. 8 Workshop, A05 District, Supporting Area, Khorgos City, Ili Kazak Autonomous Prefecture, Xinjiang Uygur Autonomous Region Patentee after: Kangchen Pharmaceutical (Horgos) Co.,Ltd. Address before: 028100 North Road 2, Ganqika Industrial Park, Horqin Left Back Banner, Tongliao City, Inner Mongolia Patentee before: Kangchen Pharmaceutical (Inner Mongolia) Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060816 |